Skip to main content

Table 2 Age distribution of included patients of which test results of all 3 assays are available (n = 11,333).

From: HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows

Age (years)

Included samples (N)

Age distribution of tested cohort (DuSC)

Age distribution of Dutch screening population

HC2 hrHPV prevalence

%(N)

cobas hrHPV prevalence

%(N)

Aptima hrHPV prevalence

%(N)

Overall hrHPV prevalence

29–33

1,191

10.5%

10.5%

19.1% (228)

19.7% (235)

17.3% (206)

18.7 ± 1.2%

34–38

1,317

11.6%

11.7%

11.7% (154)

11.5% (152)

10.6% (140)

11.3 ± 0.6%

39–43

1,775

15.7%

16.3%

9.0% (159)

8.0% (142)

7.3% (130)

8.1 ± 0.9%

44–48

1,928

17.0%

16.9%

7.7% (148)

7.1% (137)

6.3% (122)

7.0 ± 0.7%

49–53

1,870

16.5%

16.4%

6.3% (117)

5.4% (101)

5.4% (101)

5.7 ± 0.5%

54–58

1,703

15.0%

14.7%

5.4% (92)

5.0% (86)

4.9% (84)

5.1 ± 0.3%

59–63

1,549

13.7%

13.6%

3.9% (61)

4.3% (66)

4.3% (66)

4.2 ± 0.2%

Total (N)

11,333

  

959

919

849

 
  1. Number of included samples per age group and age distribution of study cohort vs age distribution of the Dutch screening program; and hrHPV prevalences per assay and overall mean